Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia

NCT04016129 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT04016129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04016129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 1, 2027
Completion date
June 30, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia